Tirzepatide is a weekly injection that targets two receptors: GLP-1 and GIP. Both of these receptors are involved in hunger control and blood sugar regulation. It is FDA-approved for type 2 diabetes and obesity.

Which one should I consider for fat loss?

Tirzepatide is the clear choice today. It has Phase 3 trial data showing up to roughly 20% body weight loss [verify: source] and FDA approval. Cagrilintide has no standalone approval and very limited solo human data. This is general guidance, not personalized medical advice.

Tirzepatide vs Cagrilintide: Which Burns More Fat?

Q: What is cagrilintide?

Cagrilintide is a long-acting copy of amylin, a hormone released by the pancreas after eating. It signals fullness through amylin receptors. It has no standalone FDA approval as of 2026 and is still in clinical trials [verify: source].

Q: How do tirzepatide and cagrilintide work differently?

Tirzepatide targets GLP-1 and GIP receptors, two gut hormone pathways linked to hunger and insulin. Cagrilintide targets amylin receptors, a pancreas hormone pathway linked to fullness signals. They work through completely separate systems.

Built by medical professionals, gym rats, and experienced biohackers

Tirzepatide is an approved drug with strong clinical evidence; cagrilintide is still experimental and does not yet have a standalone approval.

Quick Answer
Tirzepatide is for people who want a well-studied, FDA-approved option with clear weight loss data. Cagrilintide is an experimental amylin peptide without standalone approval yet. The verdict: tirzepatide is the only practical choice right now; cagrilintide is years away from being a standalone alternative .

What Is Tirzepatide?

Tirzepatide (brand names Mounjaro and Zepbound) is a weekly injection that copies two gut hormones at once. These are glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).

Both of these hormones help regulate hunger and blood sugar. Hitting two receptors at once is likely why tirzepatide produces larger fat loss results than older single-receptor drugs . It received FDA approval for type 2 diabetes in 2022 and for weight loss in 2023 .

What Is Cagrilintide?

Cagrilintide is a long-acting copy of amylin, a hormone your pancreas releases right after you eat.

Natural amylin slows stomach emptying and tells the brain that the meal is done. Cagrilintide stays in the body much longer than natural amylin , so it extends that fullness signal.

As of 2026, cagrilintide has no standalone FDA approval . Most of its human evidence comes from the CagriSema trial, where it was studied alongside semaglutide rather than on its own. Doses used in trials ranged from 0.16 mg to 4.5 mg per week .

How Do Tirzepatide and Cagrilintide Work Differently?

These two drugs use completely separate pathways in the body.

Tirzepatide binds to GLP-1 and GIP receptors. These are gut hormone receptors that affect hunger, insulin release, and how fast food moves through your stomach. Cagrilintide binds to amylin receptors, which are linked to a different fullness signal from the pancreas.

Mechanism: Tirzepatide targets two gut hormone receptors. Cagrilintide targets the amylin system.

Primary use: Tirzepatide is approved for obesity and type 2 diabetes. Cagrilintide has no approved standalone use.

Typical research dose:
- Tirzepatide: 2.5 mg to 15 mg per week
- Cagrilintide: 0.16 mg to 4.5 mg per week in trials

Onset: Tirzepatide appetite effects typically begin within 1 to 2 weeks . Standalone onset data for cagrilintide is limited because most studies use it in combination .

Evidence level: Tirzepatide has completed Phase 3 trials showing up to roughly 20% body weight reduction at the highest dose . Cagrilintide's standalone human evidence is very limited. Honest assessment: cagrilintide as a solo drug is not yet supported by the same quality of evidence.

If you are running a tirzepatide protocol, DoseVault makes it easy to track your weekly injection, dose changes, and body measurements so you can see your progress clearly over time.

Tirzepatide vs Cagrilintide: Side-by-Side Comparison

Feature	Tirzepatide	Cagrilintide
Receptor targets	GLP-1 and GIP	Amylin receptors
Injection frequency	Once a week	Once a week (in trials)
Typical trial dose range	2.5 to 15 mg/week	0.16 to 4.5 mg/week
FDA approval status	Approved for obesity and diabetes	Not approved standalone
Weight loss evidence	Phase 3 data, up to roughly 20%	Limited standalone data
Where evidence comes from	Solo clinical trials	Mostly CagriSema combination study

Which One Do People Pick, and When?

There is no real competition between these two right now.

Tirzepatide is widely available, FDA-approved, and covered by some insurance plans. Anyone seeking a weight-loss medication today will use tirzepatide or a similar approved drug.

Cagrilintide is not available as a standalone prescription. People following the drug development space are watching its trial results, but it is not a current alternative to tirzepatide.

This is general guidance, not personalized medical advice. A licensed clinician can help you decide which approved options fit your specific health profile.

Disclaimer

This page is for educational purposes only. It is not medical advice. Nothing on this page should be used to diagnose, treat, cure, or prevent any condition. Always consult a qualified healthcare provider before starting any medication or changing your current plan.

Built by medical professionals, gym rats, and experienced biohackers

Track your tirzepatide doses, weight changes, and side effects with DoseVault, a tool built for people who want a clear, organized record of their protocol.